Keeping gene expression in check: eliciting the role of transcription in the maintenance of genome integrity.

Objetivo

Genomic integrity is essential for accurate gene expression and epigenetic inheritance. On the other hand, a prolonged transcriptional arrest can challenge genome stability, contributing to genetic and epigenetic defects and the mechanisms of ageing and disease.

Here we aim to identify the molecular mechanisms that couple transcriptional arrest to chromatin alteration and repair. We wish to explore the idea that transcription suppresses cellular toxicity and preserves genetic and epigenetic inheritance.

Towards these goals our work will be focused on:

1. Deciphering the molecular events impinging on the manner cells respond when the progress of a transcribing RNA polymerase II is blocked.

2. Exploring a novel, so far unanticipated function of key players of the transcription-associated repair pathways, such as the Cockayne Syndrome (CS) proteins, not related to repair.

3. Understanding the role of transcription in chemotherapeutic-driven toxicity.

4. Investigating novel post-translational modifications of CS and determining their function.

These objectives will be addressed using advanced proteomics and genome wide technologies in combination with biochemical and cellular techniques in normal human cells and a large battery of patient-derived cell lines. Our rational is that better understanding of CS function will help reach our ultimate goal, which is to identify the regulatory cascades involved in the interplay between genomic stability and transcription. The novel key idea put forward in this proposal is that active transcription itself directly contributes to genome integrity. While the role of DNA damage-driven transcription blockage in promoting repair is well established, the protective role of active transcription in genome stability is entirely unexplored.

If successful, the proposed studies may help reveal the underlying causes of related disorders and explain their clinical features.

Ámbito científico

Régimen de financiación

ERC-SG - ERC Starting Grant

Institución de acogida

EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXANDROS FLEMINGK

Aportación de la UE

€ 1 500 000,00

Dirección

FLEMING STREET 34
16672 Vari-Athens
Grecia

Región

Αττική Aττική Ανατολική Αττική

Tipo de actividad

Research Organisations

Investigador principal

Maria Fousteri (Dr.)

Contacto administrativo

Giannis Arvithas (Mr.)

Enlaces

Contactar con la organización Sitio web

Coste total

Sin datos

Beneficiarios (1)